In this study, we aimed to evaluate the binding kinetics and pharmacokinetics of 15a for murine CCR2 (mCCR2) and determine whether this CCR2 antagonist is effective in an apoE−/− mouse model of atherosclerosis. This evidence concerns the gene CCR2 and atherosclerosis.